SageView Advisory Group LLC Increases Stock Position in Medtronic PLC $MDT

Key Points

• SageView Advisory Group increased its Medtronic stake by 164.8% in Q3, buying 15,062 shares to hold 24,204 shares worth $2.305 million, while roughly 82.06% of MDT is owned by hedge funds and other institutional investors.
• Medtronic beat quarterly estimates with $1.36 EPS (vs. $1.34 expected) and $9.02 billion in revenue (vs. $8.89 billion), and set FY2026 guidance of 5.62–5.66 EPS versus analysts’ average forecast of about 5.46.
• The company announced a strategic acquisition of Scientia Vascular for $550 million to bolster its neurovascular offerings and disclosed a quarterly dividend of $0.71 (annualized $2.84, ~3.2% yield; ex-dividend March 27).

SageView Advisory Group LLC grew its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 164.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,204 shares of the medical technology company's stock after purchasing an additional 15,062 shares during the period. SageView Advisory Group LLC's holdings in Medtronic were worth $2,305,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of MDT. Artisan Partners Limited Partnership raised its position in Medtronic by 2.6% in the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company's stock worth $117,579,000 after acquiring an additional 31,314 shares in the last quarter. AXQ Capital LP boosted its position in shares of Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company's stock worth $862,000 after purchasing an additional 2,013 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company's stock worth $13,170,000 after purchasing an additional 54,898 shares in the last quarter. Applied Finance Capital Management LLC acquired a new position in shares of Medtronic during the 3rd quarter worth $1,308,000. Finally, Willis Investment Counsel grew its stake in shares of Medtronic by 5.0% during the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company's stock worth $38,274,000 after purchasing an additional 19,192 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Price Performance

Medtronic stock opened at $88.97 on Thursday. The firm has a market capitalization of $114.23 billion, a PE ratio of 24.78, a P/E/G ratio of 2.26 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm's 50-day simple moving average is $98.31 and its 200 day simple moving average is $96.94. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic's dividend payout ratio (DPR) is 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced a definitive agreement to acquire Scientia Vascular for $550 million to strengthen its neurovascular access and therapeutic portfolio — a strategic buy that expands Medtronic’s stroke/aneurysm workflow coverage and supports longer-term growth in neurovascular procedures. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Positive Sentiment: New data highlight clinical benefit for the Symplicity Spyral renal denervation system — evidence that can support commercial adoption and reimbursement discussions for hypertension interventions. Medtronic data highlights clinical benefit of Symplicity Spyral renal denervation
• Positive Sentiment: Medtronic elevated long-time executive Sean Haag to president of its ENT business and to the neuroscience leadership team — an internal leadership move intended to accelerate ENT strategy execution and cross-group coordination. Medtronic elevates Sean Haag to president of ENT
• Neutral Sentiment: Management presentations/transcripts from investor conferences (Leerink and Barclays) provide updated commentary on strategy, margins and product cadence but didn’t introduce a clear new catalyst — useful for modelling but not market-moving on their own. Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and valuation checks are flagging recent share-price weakness and asking whether MDT is attractively priced after declines — this frames investor debate between buying the dip vs. waiting for clearer growth signals. Is Medtronic (MDT) Pricing Look Attractive After Recent Share Price Weakness
• Neutral Sentiment: Analyst coverage roundup offers a range of opinions and price targets — helpful for tracking consensus but not a single directional catalyst. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Negative Sentiment: Competitor Intuitive Surgical’s strong momentum with da Vinci 5 and expanding procedure volumes underscores robotic platform adoption that could pressure legacy procedure mix and market share dynamics in some surgical categories. Intuitive Surgical Poised for Growth in 2026 on da Vinci 5 Momentum
• Negative Sentiment: NeuroPace’s product and reimbursement progress (RNS adoption, AI seizure detection) highlight competitive advances in neuromodulation that may influence neurology market dynamics where Medtronic also competes. NeuroPace's Seizure ID and New Indication Could Expand RNS Demand

Analyst Ratings Changes

Several analysts recently commented on the stock. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a "neutral" rating in a research note on Wednesday, November 19th. Citigroup started coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They set a "buy" rating and a $117.00 target price on the stock. Sanford C. Bernstein increased their target price on shares of Medtronic from $111.00 to $112.00 and gave the company an "outperform" rating in a report on Friday, January 9th. Robert W. Baird reduced their price target on shares of Medtronic from $103.00 to $100.00 and set a "neutral" rating for the company in a research report on Wednesday, February 18th. Finally, William Blair raised Medtronic from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $110.74.

Insider Activity

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.